<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>NTRK Fusion-Positive Cancer - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-source {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            background: #e2e8f0;
            color: #334155;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .evidence-support:hover,
        .evidence-source:hover {
            transform: translateY(-1px);
            box-shadow: 0 4px 10px rgba(0,0,0,0.08);
        }

        .source-HUMAN_CLINICAL { background: #e0f2fe; color: #075985; }
        .source-MODEL_ORGANISM { background: #fef9c3; color: #854d0e; }
        .source-IN_VITRO { background: #ede9fe; color: #5b21b6; }
        .source-COMPUTATIONAL { background: #cffafe; color: #0e7490; }
        .source-OTHER { background: #e5e7eb; color: #374151; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Histopathology */
        .histopathology-box {
            background: #fff7ed;
            border-left: 4px solid #fb923c;
        }
        .histopathology-box .item-name { color: #9a3412; }
        .histopathology-box .item-desc { color: #c2410c; }

        .histopathology-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #ffedd5;
            color: #c2410c;
        }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    

    

    
    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>NTRK Fusion-Positive Cancer</span>
        </nav>

        <header class="page-header">
            <h1>NTRK Fusion-Positive Cancer</h1>
            <div class="header-meta">
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0700215" target="_blank">
                        MONDO:0700215
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">neoplasm</span>
                
            </div>
            
            <p style="margin-top: 16px; font-size: 1rem; line-height: 1.6; opacity: 0.95; position: relative;">
                NTRK fusion-positive cancer is a tumor-agnostic molecular diagnosis defined by chromosomal rearrangements involving NTRK1, NTRK2, or NTRK3 genes encoding neurotrophic tyrosine receptor kinases (TRK). These fusions create constitutively active chimeric proteins that drive oncogenesis across diverse tumor types. NTRK fusions occur at varying frequencies: very common in secretory breast carcinoma and infantile fibrosarcoma (&gt;90%), but rare (&lt;1%) in common solid tumors. The development of TRK inhibitors larotrectinib and entrectinib represents a paradigm shift in oncology, providing highly effective tumor-agnostic targeted therapy based solely on the presence of NTRK fusions regardless of tumor histology or site of origin.
            </p>
            
        </header>

        <!-- Stats bar -->
        <div class="stats-bar">
            <div class="stat-item">
                <div class="stat-value">3</div>
                <div class="stat-label">Mechanisms</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">1</div>
                <div class="stat-label">Histopathology</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">2</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">3</div>
                <div class="stat-label">Genes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">3</div>
                <div class="stat-label">Treatments</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">3</div>
                <div class="stat-label">Subtypes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Trials</div>
            </div>
        </div>

        <!-- Classifications -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üè∑</div>
                <h2 class="card-title">Classifications</h2>
            </div>
            
            <div style="margin-bottom: 16px;">
                <div class="classification-category">Harrison's Chapter</div>
                <div class="tag-list">
                    
                    <span class="tag tag-classification">cancer</span>
                    
                    <span class="tag tag-classification">solid tumor</span>
                    
                </div>
            </div>
            
            
            
            <div style="margin-bottom: 16px;">
                <div class="classification-category">ICD-O Morphology</div>
                <div class="tag-list">
                    <span class="tag tag-classification">Carcinoma</span>
                </div>
            </div>
            
            
            
            
        </div>
        

        <!-- Subtypes -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #eef2ff; color: #4f46e5;">‚óÜ</div>
                <h2 class="card-title">Subtypes</h2>
                <span class="card-count">3</span>
            </div>
            
            <div class="item-box subtype-box">
                <div class="item-name">NTRK1 Fusion-Positive Cancer</div>
                
                <div class="item-desc">Fusions involving NTRK1 (encoding TRKA) are common in papillary thyroid cancer, lung adenocarcinoma, and colorectal cancer. Common fusion partners include TPM3, TPR, and LMNA.</div>
                
                
    
    
            </div>
            
            <div class="item-box subtype-box">
                <div class="item-name">NTRK2 Fusion-Positive Cancer</div>
                
                <div class="item-desc">Fusions involving NTRK2 (encoding TRKB) are less common than NTRK1 or NTRK3 fusions. Found in various tumor types including gliomas.</div>
                
                
    
    
            </div>
            
            <div class="item-box subtype-box">
                <div class="item-name">NTRK3 Fusion-Positive Cancer</div>
                
                <div class="item-desc">Fusions involving NTRK3 (encoding TRKC) are characteristic of secretory breast carcinoma and infantile fibrosarcoma. ETV6-NTRK3 is the classic fusion in these tumors.</div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Pathophysiology -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">‚öô</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">3</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">NTRK Gene Fusion and Constitutive TRK Activation</div>
                
                <div class="item-desc">Chromosomal rearrangements fuse the kinase domain of NTRK genes with various upstream partners that provide dimerization domains. This creates constitutively active chimeric TRK proteins that signal independently of neurotrophin ligands.</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        protein tyrosine kinase activity
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0004713" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ‚Üë INCREASED
    </span>
    
    
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39988443" target="_blank">PMID:39988443</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Fusion variations of neurotrophic receptor tyrosine kinase (NTRK) are oncogenic drivers in various solid tumors such as breast cancer, salivary gland carcinoma, infant fibrosarcoma, etc."</div>
                
                
                <div class="evidence-explanation">Supports NTRK fusions as oncogenic drivers across solid tumors.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">RAS-MAPK Pathway Activation</div>
                
                <div class="item-desc">Constitutive TRK activation drives the RAS-RAF-MEK-ERK signaling cascade, promoting uncontrolled cell proliferation. This is a major effector pathway of TRK-mediated oncogenesis.</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        MAPK cascade
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0000165" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ‚Üë INCREASED
    </span>
    
    
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">PI3K-AKT Pathway Activation</div>
                
                <div class="item-desc">TRK activation recruits PI3K and stimulates AKT-mTOR signaling, promoting cell survival and resistance to apoptosis. Combined with MAPK activation, this drives aggressive tumor growth.</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        phosphatidylinositol 3-kinase signaling
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0014065" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ‚Üë INCREASED
    </span>
    
    
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Histopathology -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ffedd5; color: #c2410c;">‚ú∂</div>
                <h2 class="card-title">Histopathology</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box histopathology-box">
                <div class="item-name">
                    Histology-Agnostic Solid Tumors
                    
                    <span class="histopathology-freq">COMMON</span>
                    
                </div>
                
                <div class="item-desc">NTRK gene fusions are found across cancer types.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36914665" target="_blank">PMID:36914665</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"NTRK gene fusions are rare somatic mutations found across cancer types with"</div>
                
                
                <div class="evidence-explanation">Abstract notes NTRK fusions occur across cancer types.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Causal Graph -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #e0e7ff; color: #4f46e5;">‚¨°</div>
                <h2 class="card-title">Causal Graph</h2>
            </div>
            
            <div class="graph-warning">
                <strong>Referential integrity issues (1):</strong>
                <ul>
                    
                    <li>Target &#39;PLCgamma Pathway Activation&#39; (from &#39;NTRK Gene Fusion and Constitutive TRK Activation&#39;) not found in named elements</li>
                    
                    
                </ul>
            </div>
            
            <div class="mermaid-container">
                <pre class="mermaid">graph TD
    PLCgamma_Pathway_Activation[&#34;PLCgamma Pathway Activation&#34;]
    NTRK_Gene_Fusion_and_Constitutive_TRK_Activation[&#34;NTRK Gene Fusion and Constitutive TRK Activation&#34;]
    RAS_MAPK_Pathway_Activation[&#34;RAS-MAPK Pathway Activation&#34;]
    PI3K_AKT_Pathway_Activation[&#34;PI3K-AKT Pathway Activation&#34;]

    NTRK_Gene_Fusion_and_Constitutive_TRK_Activation --&gt; RAS_MAPK_Pathway_Activation
    NTRK_Gene_Fusion_and_Constitutive_TRK_Activation --&gt; PI3K_AKT_Pathway_Activation
    NTRK_Gene_Fusion_and_Constitutive_TRK_Activation -.-&gt; PLCgamma_Pathway_Activation

    style PLCgamma_Pathway_Activation fill:#fee2e2,stroke:#dc2626,stroke-dasharray: 5 5
    style NTRK_Gene_Fusion_and_Constitutive_TRK_Activation fill:#dbeafe
    style RAS_MAPK_Pathway_Activation fill:#dbeafe
    style PI3K_AKT_Pathway_Activation fill:#dbeafe</pre>
            </div>
        </div>
        

        <!-- Phenotypes -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">‚óè</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Tumor Growth
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">General</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0002664" target="_blank">
                            HP:0002664
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Fatigue
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Constitutional</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0012378" target="_blank">
                            HP:0012378
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    
            </div>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">üß¨</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">3</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    NTRK1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Somatic Gene Fusions)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33258061" target="_blank">PMID:33258061</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"NTRK gene fusions are sporadic genetic alterations that can occur across tumor entities."</div>
                
                
                <div class="evidence-explanation">Abstract notes NTRK gene fusions occur across tumor entities, supporting NTRK1 fusion involvement.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    NTRK2
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Somatic Gene Fusions)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33258061" target="_blank">PMID:33258061</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"NTRK gene fusions are sporadic genetic alterations that can occur across tumor entities."</div>
                
                
                <div class="evidence-explanation">Abstract notes NTRK gene fusions occur across tumor entities, supporting NTRK2 fusion involvement.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    NTRK3
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Somatic Gene Fusions)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33258061" target="_blank">PMID:33258061</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"NTRK gene fusions are sporadic genetic alterations that can occur across tumor entities."</div>
                
                
                <div class="evidence-explanation">Abstract notes NTRK gene fusions occur across tumor entities, supporting NTRK3 fusion involvement.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">üíä</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">3</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Larotrectinib
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Highly selective TRK inhibitor approved for adult and pediatric solid tumors with NTRK gene fusions. Demonstrates remarkable efficacy across tumor types with overall response rate of approximately 75% and durable responses. First tumor-agnostic TRK inhibitor approval.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33258061" target="_blank">PMID:33258061</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"If NTRK gene fusions are detected, TRK inhibitors such as entrectinib and larotrectinib can be used regardless of the tumor entity."</div>
                
                
                <div class="evidence-explanation">Abstract states larotrectinib can be used when NTRK fusions are detected.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Entrectinib
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">TRK inhibitor with additional activity against ROS1 and ALK. Approved for NTRK fusion-positive solid tumors in adults and children. Penetrates CNS, providing activity against brain metastases.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33258061" target="_blank">PMID:33258061</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"If NTRK gene fusions are detected, TRK inhibitors such as entrectinib and larotrectinib can be used regardless of the tumor entity."</div>
                
                
                <div class="evidence-explanation">Abstract states entrectinib can be used when NTRK fusions are detected.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Repotrectinib
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Next-generation TRK inhibitor designed to overcome resistance mutations including solvent front mutations (G595R, G623R). Option for patients who progress on first-generation TRK inhibitors.</div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üî¨</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    NTRK Fusion Detection
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- Clinical Trials -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: NTRK Fusion-Positive Cancer
description: &gt;-
  NTRK fusion-positive cancer is a tumor-agnostic molecular diagnosis defined by
  chromosomal rearrangements involving NTRK1, NTRK2, or NTRK3 genes encoding neurotrophic
  tyrosine receptor kinases (TRK). These fusions create constitutively active chimeric
  proteins that drive oncogenesis across diverse tumor types. NTRK fusions occur at
  varying frequencies: very common in secretory breast carcinoma and infantile fibrosarcoma
  (&gt;90%), but rare (&lt;1%) in common solid tumors. The development of TRK inhibitors
  larotrectinib and entrectinib represents a paradigm shift in oncology, providing
  highly effective tumor-agnostic targeted therapy based solely on the presence of
  NTRK fusions regardless of tumor histology or site of origin.
categories:
- Molecularly-Defined Cancer
- Tumor-Agnostic Indication
parents:
- neoplasm
has_subtypes:
- name: NTRK1 Fusion-Positive Cancer
  description: &gt;-
    Fusions involving NTRK1 (encoding TRKA) are common in papillary thyroid cancer,
    lung adenocarcinoma, and colorectal cancer. Common fusion partners include TPM3,
    TPR, and LMNA.
- name: NTRK2 Fusion-Positive Cancer
  description: &gt;-
    Fusions involving NTRK2 (encoding TRKB) are less common than NTRK1 or NTRK3
    fusions. Found in various tumor types including gliomas.
- name: NTRK3 Fusion-Positive Cancer
  description: &gt;-
    Fusions involving NTRK3 (encoding TRKC) are characteristic of secretory breast
    carcinoma and infantile fibrosarcoma. ETV6-NTRK3 is the classic fusion in these
    tumors.
pathophysiology:
- name: NTRK Gene Fusion and Constitutive TRK Activation
  description: &gt;-
    Chromosomal rearrangements fuse the kinase domain of NTRK genes with various
    upstream partners that provide dimerization domains. This creates constitutively
    active chimeric TRK proteins that signal independently of neurotrophin ligands.
  evidence:
  - reference: PMID:39988443
    supports: SUPPORT
    snippet: &#34;Fusion variations of neurotrophic receptor tyrosine kinase (NTRK) are oncogenic drivers in various solid tumors
      such as breast cancer, salivary gland carcinoma, infant fibrosarcoma, etc.&#34;
    explanation: &#34;Supports NTRK fusions as oncogenic drivers across solid tumors.&#34;
  biological_processes:
  - preferred_term: protein tyrosine kinase activity
    modifier: INCREASED
    term:
      id: GO:0004713
      label: protein tyrosine kinase activity
  downstream:
  - target: RAS-MAPK Pathway Activation
    description: TRK activation drives RAS-RAF-MEK-ERK signaling
  - target: PI3K-AKT Pathway Activation
    description: TRK activation stimulates PI3K-AKT-mTOR survival signaling
  - target: PLCgamma Pathway Activation
    description: TRK activation engages phospholipase C gamma signaling
- name: RAS-MAPK Pathway Activation
  description: &gt;-
    Constitutive TRK activation drives the RAS-RAF-MEK-ERK signaling cascade,
    promoting uncontrolled cell proliferation. This is a major effector pathway
    of TRK-mediated oncogenesis.
  biological_processes:
  - preferred_term: MAPK cascade
    modifier: INCREASED
    term:
      id: GO:0000165
      label: MAPK cascade
- name: PI3K-AKT Pathway Activation
  description: &gt;-
    TRK activation recruits PI3K and stimulates AKT-mTOR signaling, promoting
    cell survival and resistance to apoptosis. Combined with MAPK activation,
    this drives aggressive tumor growth.
  biological_processes:
  - preferred_term: phosphatidylinositol 3-kinase signaling
    modifier: INCREASED
    term:
      id: GO:0014065
      label: phosphatidylinositol 3-kinase signaling
histopathology:
- name: Histology-Agnostic Solid Tumors
  finding_term:
    preferred_term: Malignant Solid Neoplasm
    term:
      id: NCIT:C132146
      label: Malignant Solid Neoplasm
  frequency: COMMON
  description: NTRK gene fusions are found across cancer types.
  evidence:
  - reference: PMID:36914665
    supports: SUPPORT
    snippet: &#34;NTRK gene fusions are rare somatic mutations found across cancer types with&#34;
    explanation: Abstract notes NTRK fusions occur across cancer types.

phenotypes:
- category: General
  name: Tumor Growth
  frequency: VERY_FREQUENT
  description: &gt;-
    Clinical presentation depends on tumor type and location. NTRK fusions
    can occur in virtually any solid tumor type.
  phenotype_term:
    preferred_term: Neoplasm
    term:
      id: HP:0002664
      label: Neoplasm
- category: Constitutional
  name: Fatigue
  frequency: FREQUENT
  description: &gt;-
    Constitutional symptoms are common in advanced disease regardless of
    tumor histology.
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
biochemical:
- name: NTRK Fusion Detection
  notes: &gt;-
    Multiple testing methods detect NTRK fusions including RNA-based NGS (preferred),
    DNA-based NGS, FISH, and immunohistochemistry for pan-TRK expression. RNA-based
    testing captures the full spectrum of fusion partners.
genetic:
- name: NTRK1
  association: Somatic Gene Fusions
  notes: &gt;-
    NTRK1 encodes TRKA receptor. Common fusion partners include TPM3, TPR, LMNA,
    and SQSTM1. Fusions are found in papillary thyroid cancer, NSCLC, colorectal
    cancer, and other tumor types.
  evidence:
  - reference: PMID:33258061
    supports: SUPPORT
    snippet: &#34;NTRK gene fusions are sporadic genetic alterations that can occur across tumor entities.&#34;
    explanation: &#34;Abstract notes NTRK gene fusions occur across tumor entities, supporting NTRK1 fusion involvement.&#34;
- name: NTRK2
  association: Somatic Gene Fusions
  notes: &gt;-
    NTRK2 encodes TRKB receptor. Less commonly involved in oncogenic fusions
    than NTRK1 or NTRK3. Found in various tumor types including gliomas.
  evidence:
  - reference: PMID:33258061
    supports: SUPPORT
    snippet: &#34;NTRK gene fusions are sporadic genetic alterations that can occur across tumor entities.&#34;
    explanation: &#34;Abstract notes NTRK gene fusions occur across tumor entities, supporting NTRK2 fusion involvement.&#34;
- name: NTRK3
  association: Somatic Gene Fusions
  notes: &gt;-
    NTRK3 encodes TRKC receptor. ETV6-NTRK3 fusion is characteristic of secretory
    breast carcinoma (&gt;90%) and infantile fibrosarcoma (&gt;90%). Also found in other
    pediatric and adult tumors.
  evidence:
  - reference: PMID:33258061
    supports: SUPPORT
    snippet: &#34;NTRK gene fusions are sporadic genetic alterations that can occur across tumor entities.&#34;
    explanation: &#34;Abstract notes NTRK gene fusions occur across tumor entities, supporting NTRK3 fusion involvement.&#34;
treatments:
- name: Larotrectinib
  description: &gt;-
    Highly selective TRK inhibitor approved for adult and pediatric solid tumors
    with NTRK gene fusions. Demonstrates remarkable efficacy across tumor types
    with overall response rate of approximately 75% and durable responses. First
    tumor-agnostic TRK inhibitor approval.
  evidence:
  - reference: PMID:33258061
    supports: SUPPORT
    snippet: &#34;If NTRK gene fusions are detected, TRK inhibitors such as entrectinib and larotrectinib can be used regardless of the tumor entity.&#34;
    explanation: &#34;Abstract states larotrectinib can be used when NTRK fusions are detected.&#34;
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Entrectinib
  description: &gt;-
    TRK inhibitor with additional activity against ROS1 and ALK. Approved for
    NTRK fusion-positive solid tumors in adults and children. Penetrates CNS,
    providing activity against brain metastases.
  evidence:
  - reference: PMID:33258061
    supports: SUPPORT
    snippet: &#34;If NTRK gene fusions are detected, TRK inhibitors such as entrectinib and larotrectinib can be used regardless of the tumor entity.&#34;
    explanation: &#34;Abstract states entrectinib can be used when NTRK fusions are detected.&#34;
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: entrectinib
      term:
        id: CHEBI:195558
        label: entrectinib
- name: Repotrectinib
  description: &gt;-
    Next-generation TRK inhibitor designed to overcome resistance mutations
    including solvent front mutations (G595R, G623R). Option for patients who
    progress on first-generation TRK inhibitors.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
disease_term:
  preferred_term: NTRK fusion positive cancer
  term:
    id: MONDO:0700215
    label: NTRK fusion positive cancer

classifications:
  icdo_morphology:
    classification_value: Carcinoma
  harrisons_chapter:
  - classification_value: cancer
  - classification_value: solid tumor
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/NTRK_Fusion_Positive_Cancer.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
</body>
</html>